Epidemiology of Cardiorenal Syndrome

Cardiology Clinics

Volumn 29, Issue 2, 2011, Pages 301-314

  Mentz, Robert J ^a   Lewis, Eldrin F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiorenal syndrome; Congestive heart failure; End of life; Epidemiology; Management

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; LOOP DIURETIC AGENT; METOPROLOL; MILRINONE; NESIRITIDE; PLACEBO; ROLOFYLLINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN ANTAGONIST;

CARDIORENAL SYNDROME; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; HEARING LOSS; HEART ASSIST DEVICE; HEART FAILURE; HEART TRANSPLANTATION; HOSPITAL CARE; HUMAN; HYPOTENSION; INCIDENCE; KIDNEY FAILURE; LONG TERM CARE; LOW DRUG DOSE; MORBIDITY; MORTALITY; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TERMINAL CARE; TINNITUS; ULTRAFILTRATION;

COMBINED MODALITY THERAPY; CYTOKINES; HEART FAILURE; HUMANS; KIDNEY FUNCTION TESTS; LONG-TERM CARE; MORTALITY; PALLIATIVE CARE; QUALITY OF LIFE; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SYNDROME; THERAPIES, INVESTIGATIONAL;

EID: 79953178969     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2011.03.004     Document Type: Review

References (116)

1. Redfield M.M., Jacobsen S.J., Burnett J.C., et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289(2):194-202.
2. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002, 106(24):3068-3072.
3. American Heart Association 2009 Heart and stroke statistical update 2009, American Heart Association, Dallas (TX).
4. Fonarow G.C. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003, 4(Suppl 7):S21-S30.
5. Evans F., Fakunding J. NHLBI Working Group: cardiorenal connections in heart failure and cardiovascular disease Available at:, Accessed January 10, 2010. http://www.nhlbi.nih.gov/meetings/workshops/cardiorenal-hf-hd.htm.
6. Hillege H.L., Nitsch D., Pfeffer M.A., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006, 113(5):671-678.
7. Dries D.L., Exner D.V., Domanski M.J., et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000, 35(3):681-689.
8. Schrier R.W. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?. J Am Coll Cardiol 2006, 47(1):1-8.
9. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351(13):1296-1305.
10. Manjunath G., Tighiouart H., Ibrahim H., et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003, 41(1):47-55.
11. Hillege H.L., Girbes A.R., de Kam P.J., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000, 102(2):203-210.
12. Shlipak M.G., Smith G.L., Rathore S.S. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol 2004, 15(8):2195-2203.
13. Harnett J.D., Foley R.N., Kent G.M., et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995, 47(3):884-890.
14. Bongartz L.G., Cramer M.J., Doevendans P.A., et al. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005, 26(1):11-17.
15. Ronco C., Haapio M., House A.A., et al. Cardiorenal syndrome. J Am Coll Cardiol 2008, 52(19):1527-1539.
16. Sarraf M., Masoumi A., Schrier R.W. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 2009, 4(12):2013-2026.
17. Liang K.V., Williams A.W., Greene E.L., et al. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 2008, 36(Suppl 1):S75-S88.
18. Krum H., Iyngkaran P., Lekawanvijit S. Pharmacologic management of the cardiorenal syndrome in heart failure. Curr Heart Fail Rep 2009, 6(2):105-111.
19. McMurray J.J. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors?. Eur Heart J 1998, 19(Suppl L):L15-L21.
20. Pokhrel N., Maharjan N., Dhakal B., et al. Cardiorenal syndrome: a literature review. Exp Clin Cardiol 2008, 13(4):165-170.
21. Slack A.J., Wendon J. The liver and kidney in critically ill patients. Blood Purif 2009, 28(2):124-134.
22. Weinfeld M.S., Chertow G.M., Stevenson L.W. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999, 138(2 Pt 1):285-290.
23. Cowie M.R., Komajda M., Murray-Thomas T., et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006, 27(10):1216-1222.
24. Heywood J.T., Fonarow G.C., Costanzo M.R., et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007, 13(6):422-430.
25. Nohria A., Hasselblad V., Stebbins A., et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008, 51(13):1268-1274.
26. Mullens W., Abrahams Z., Francis G.S., et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009, 53(7):589-596.
27. Gottlieb S.S., Abraham W., Butler J., et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002, 8(3):136-141.
28. Owan T.E., Hodge D.O., Herges R.M., et al. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. J Card Fail 2006, 12(4):257-262.
29. Krumholz H.M., Chen Y.T., Vaccarino V., et al. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. Am J Cardiol 2000, 85(9):1110-1113.
30. Butler J., Forman D.E., Abraham W.T., et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004, 147(2):331-338.
31. Forman D.E., Butler J., Wang Y., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004, 43(1):61-67.
32. Knight E.L., Glynn R.J., McIntyre K.M., et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 1999, 138(5 Pt 1):849-855.
33. Jose P., Skali H., Anavekar N., et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006, 17(10):2886-2891.
34. Smilde T.D., Hillege H.L., Navis G., et al. Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. Am Heart J 2004, 148(1):165-172.
35. Bibbins-Domingo K., Lin F., Vittinghoff E., et al. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol 2004, 44(8):1593-1600.
36. Smith G.L., Shlipak M.G., Havranek E.P., et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005, 111(10):1270-1277.
37. de Silva R., Nikitin N.P., Witte K.K., et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 2006, 27(5):569-581.
38. McAlister F.A., Ezekowitz J., Tonelli M., et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004, 109(8):1004-1009.
39. Lee D.S., Gona P., Vasan R.S., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation 2009, 119(24):3070-3077.
40. Dunlay S.M., Redfield M.M., Weston S.A., et al. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol 2009, 54(18):1695-1702.
41. Smith G.L., Lichtman J.H., Bracken M.B., et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006, 47(10):1987-1996.
42. Damman K., Navis G., Voors A.A., et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007, 13(8):599-608.
43. Smith G.L., Vaccarino V., Kosiborod M., et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?. J Card Fail 2003, 9(1):13-25.
44. Fonarow G.C., Adams K.F., Abraham W.T., et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293(5):572-580.
45. Klein L., Massie B.M., Leimberger J.D., et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 2008, 1(1):25-33.
46. Houghton A.R., Cowley A.J. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?. Int J Cardiol 1997, 59(1):7-10.
47. Ahmed A., Allman R.M., DeLong J.F., et al. Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients. South Med J 2002, 95(7):703-710.
48. Masoudi F.A., Rathore S.S., Wang Y., et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004, 110(6):724-731.
49. Al-Ahmad A., Sarnak M.J., Salem D.N., et al. Cause and management of heart failure in patients with chronic renal disease. Semin Nephrol 2001, 21(1):3-12.
50. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001, 38(4):955-962.
51. McClellan W.M., Flanders W.D., Langston R.D., et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002, 13(7):1928-1936.
52. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
53. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084.
54. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342(20):1478-1483.
55. Block G.A., Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000, 35(6):1226-1237.
56. Sadeghi H.M., Stone G.W., Grines C.L., et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003, 108(22):2769-2775.
57. Russo D., Palmiero G., De Blasio A.P., et al. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004, 44:1024-1030.
58. Ketteler M., Schlieper G., Floege J. Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 2006, 47:1027-1034.
59. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85-97.
60. Shlipak M.G., Fried L.F., Crump C., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003, 107(1):87-92.
61. Boushey C.J., Beresford S.A., Omenn G.S., et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274(13):1049-1057.
62. Gerstein H.C., Mann J.F., Yi Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286(4):421-426.
63. Taki K., Tsuruta Y., Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol 2007, 27(1):30-35.
64. Lee W.H., Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986, 73(2):257-267.
65. Leier C.V., Dei Cas L., Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994, 128(3):564-574.
66. Salvador D.R., Rey N.R., Ramos G.C., et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005, 3. CD003178.
67. Shlipak M.G. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003, 138(11):917-924.
68. Gattis W.A., O'Connor C.M., Leimberger J.D., et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol 2003, 91(2):169-174. OPTIME.
69. Metra M., Torp-Pedersen C., Cleland J.G., et al. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail 2007, 9(9):901-909.
70. Butler J., Young J.B., Abraham W.T., et al. Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol 2006, 47(12):2462-2469.
71. Fonarow G.C., Abraham W.T., Albert N.M., et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008, 52(3):190-199.
72. Butler J., Arbogast P.G., BeLue R., et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002, 40(9):1589-1595.
73. Sackner-Bernstein J.D., Skopicki H.A., Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111(12):1487-1491.
74. Arora R.R., Venkatesh P.K., Molnar J. Short and long-term mortality with nesiritide. Am Heart J 2006, 152(6):1084-1090.
75. ASCEND-HF Double-blind, placebo-controlled, multicenter acute study of clinical effectiveness of nesiritide in subjects with decompensated heart failure Available at:, Accessed January 10, 2010. http://clinicaltrials.gov/ct2/show/NCT00475852.
76. Schrier R.W., Gross P., Gheorghiade M., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355(20):2099-2112.
77. Gheorghiade M., Niazi I., Ouyang J., et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003, 107(21):2690-2696.
78. Gheorghiade M., Gattis W.A., O'Connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291(16):1963-1971.
79. Cotter G., Dittrich H.C., Weatherley B.D., et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008, 14(8):631-640.
80. Kazory A., Ross E.A. Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. Circulation 2008, 117(7):975-983.
81. Jessup M., Costanzo M.R. The cardiorenal syndrome: do we need a change of strategy or a change of tactics?. J Am Coll Cardiol 2009, 53(7):597-599.
82. Khalifeh N., Vychytil A., Hörl W.H. The role of peritoneal dialysis in the management of treatment-resistant congestive heart failure: a European perspective. Kidney Int Suppl 2006, 103:S72-S75.
83. Liang K.V., Hiniker A.R., Williams A.W., et al. Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center. J Card Fail 2006, 12(9):707-714.
84. Costanzo M.R., Guglin M.E., Saltzberg M.T., et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007, 49(6):675-683.
85. Krishnan A., Oreopoulos D.G. Peritoneal dialysis in congestive heart failure. Adv Perit Dial 2007, 23:82-89.
86. Gotloib L., Fudin R., Yakubovich M., et al. Peritoneal dialysis in refractory end-stage congestive heart failure: a challenge facing a no-win situation. Nephrol Dial Transplant 2005, 20(Suppl 7):vii32-vii36.
87. Stack A.G., Molony D.A., Rahman N.S., et al. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int 2003, 64(3):1071-1079.
88. Couchoud C., Stengel B., Landais P., et al. The renal epidemiology and information network (REIN): a new registry for end-stage renal disease in France. Nephrol Dial Transplant 2006, 21:411-418.
89. Kirchgessner J., Pera-Chang M., Klinkner G., et al. Satisfaction with care in peritoneal dialysis patients. Kidney Int 2006, 70:1325-1331.
90. Frimat L., Durand P.Y., Loos-Avay C., et al. Impact of first dialysis modality on outcome of patients contraindicated for kidney transplant. Perit Dial Int 2006, 26:231-239.
91. Gheorghiade M., Filippatos G. Reassessing treatment of acute heart failure syndromes: the ADHERE registry. Eur Heart J 2005, 7(Suppl B):B13-B19.
92. Roy P., Bouchard J., Amyot R., et al. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. Am J Kidney Dis 2006, 48(4):645-651.
93. Ruggenenti P., Perna A., Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril efficacy in nephropathy. J Am Soc Nephrol 2001, 12(12):2832-2837.
94. Bakris G.L., Weir M.R. Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med 2000, 160:685-693.
95. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316(23):1429-1435.
96. Ljungman S., Kjekshus J., Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992, 70(4):479-487.
97. MacDowall P., Kalra P.A., O'Donoghue D.J., et al. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet 1998, 352(9121):13-16.
98. Shlipak M.G., Browner W.S., Noguchi H., et al. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Am J Med 2001, 110(6):425-433.
99. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341(10):709-717.
100. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997, 336(8):525-533.
101. Wilson S.R., Mudge G.H., Stewart G.C., et al. Evaluation for a ventricular assist device: selecting the appropriate candidate. Circulation 2009, 119(16):2225-2232.
102. Sandner S.E., Zimpfer D., Zrunek P., et al. Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg 2009, 87(4):1072-1078.
103. Kamdar F., Boyle A., Liao K., et al. Effects of centrifugal, axial, and pulsatile left ventricular assist device support on end-organ function in heart failure patients. J Heart Lung Transplant 2009, 28(4):352-359.
104. Heart disease and stroke statistics-2004 update 2000, American Heart Association, Dallas (TX).
105. Stevenson W.G., Stevenson L.W. Prevention of sudden death in heart failure. J Cardiovasc Electrophysiol 2001, 12(1):112-114.
106. Pantilat S.Z., Steimle A.E. Palliative care for patients with heart failure. JAMA 2004, 291(20):2476-2482.
107. Hauptman P.J., Havranek E.P. Integrating palliative care into heart failure care. Arch Intern Med 2005, 165(4):374-378.
108. Anker S.D., Chua T.P., Ponikowski P., et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997, 96(2):526-534.
109. Aaronson K.D., Schwartz J.S., Chen T.M., et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997, 95(12):2660-2667.
110. Kittleson M., Hurwitz S., Shah M.R., et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol 2003, 41(11):2029-2035.
111. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001, 345(20):1435-1443.
112. Goodlin S.J. Palliative care in congestive heart failure. J Am Coll Cardiol 2009, 54(5):386-396.
113. Phillips C.O., Wright S.M., Kern D.E., et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004, 291(11):1358-1367.
114. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group. J Am Coll Cardiol 1983, 2(4):755-763.
115. Rabow M.W., Dibble S.L., Pantilat S.Z., et al. The comprehensive care team: a controlled trial of outpatient palliative medicine consultation. Arch Intern Med 2004, 164(1):83-91.
116. Brumley R., Enguidanos S., Jamison P., et al. Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care. J Am Geriatr Soc 2007, 55(7):993-1000.